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ABSTRACT
O-GlcNAcylation is an unusual form of protein glycosylation, where a single-sugar [GlcNAc (N-
acetylglucosamine)] is added (via β-attachment) to the hydroxyl moiety of serine and threonine
residues of nuclear and cytoplasmic proteins. A complex and extensive interplay exists between
O-GlcNAcylation and phosphorylation. Many phosphorylation sites are also known glycosylation
sites, and this reciprocal occupancy may produce different activities or alter the stability in a
target protein. The interplay between these two post-translational modiﬁcations is not always
reciprocal, as some proteins can be concomitantly phosphorylated and O-GlcNAcylated, and
the adjacent phosphorylation or O-GlcNAcylation can regulate the addition of either moiety.
IncreasedcardiovascularproductionofROS(reactiveoxygenspecies),termedoxidative stress,has
been consistently reported in various chronic diseases and in conditions where O-GlcNAcylation
has been implicated as a contributing mechanism for the associated organ injury/protection (for
example, diabetes, Alzheimer’s disease, arterial hypertension, aging and ischaemia). In the present
review, we will brieﬂy comment on general aspects of O-GlcNAcylation and provide an overview
of what has been reported for this post-translational modiﬁcation in the cardiovascular system.
We will then speciﬁcally address whether signalling molecules involved in redox signalling can
be modiﬁed by O-GlcNAc (O-linked GlcNAc) and will discuss the critical interplay between
O-GlcNAcylation and ROS generation. Experimental evidence indicates that the interactions
between O-GlcNAcylation and oxidation of proteins are important not only for cell regulation
in physiological conditions, but also under pathological states where the interplay may become
dysfunctional and thereby exacerbate cellular injury.
Key words: cardiovascular system, diabetes, inﬂammation, O-linked N-acetylglucosamine (O-GlcNAc), oxidative stress,
phosphorylation.
Abbreviations: AGE, advanced glycation end product; BEMAD, β-elimination followed by Michael addition with dithiothreitol;
DOCA, deoxycorticosterone acetate; eNOS, endothelial NO synthase; ET-1, endothelin-1; FoxO1, forkhead box O1;
GFAT, glutamine:fructose-6-phosphate amidotransferase; GlcNAc, N-acetylglucosamine; GPX1, glutathione peroxidase 1; HBP,
hexosamine biosynthesis pathway; I/R, ischaemia/reperfusion; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase;
mPTP, mitochondrial permeability transition pore; NF-κB, nuclear factor κB; OGA, β-N-acetylglucosaminidase; O-GlcNAc,
O-linked GlcNAc; O-GlcNAc-P, phosphorylated O-GlcNAc; OGT, O-GlcNAc transferase; PP1, protein phosphatase 1; PTM,
post-translational modiﬁcation; PUGNAc, O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate; RAGE,
receptor for AGEs; ROS, reactive oxygen species; shRNA, short hairpin RNA; SOD, superoxide dismutase; TPR, tetratricopeptide
repeat; VSMC, vascular smooth muscle cell.
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INTRODUCTION
A healthy vasculature is crucial to transport hormones,
gases (oxygen and carbon dioxide), nutrients and
metabolic wastes to and from every tissue in the body.
Since adequate perfusion is critical to survival, blood
distribution to the tissues/organs is under the control
of tightly regulated mechanisms that ultimately modify
the relaxation and contraction of VSMCs (vascular
smooth muscle cells). Accordingly, vascular function is
complexly regulated by a variety of signals: endocrine
and paracrine substances, sympathetic nervous system
activity, blood-borne and immune-cell-derived factors,
and by the activity of the vascular endothelium. Not
surprisingly, vascular dysfunction is linked to diverse
disorders, including diabetes, arterial hypertension, the
metabolic syndrome, chronic kidney disease, myocardial
ischaemia, congestive heart failure, stroke, retinopathy,
erectile dysfunction, cancers to name a few.
Diversity among signals that inﬂuence contrac-
tion/relaxationofVSMCsimpliesanassortmentofsignal
transduction mechanisms (receptors and intracellular
signalling pathways). Adding further complexity to the
regulation of VSMCs is the fact that many receptors and
intracellular signalling molecules are subject to PTMs
(post-translational modiﬁcations), or the reversible
additionofasmallchemicalgroup,whichcausesachange
in activity or location of a signalling protein. Table 1
illustrates PTMs regarded as important in the regulation
of protein activity, interaction with effectors, subcellular
localization, stability, trafﬁcking, translocation to lipid
rafts, aggregation and other aspects of protein function.
AmongthesePTMs,thereader’sattentionwillbedirected
to glycosylation [1,2].
Glycosylation is the site-speciﬁc enzymatic addition
of saccharides {from the Greek word s´ akkharon (sugar);
alsoknowninbiochemistryascarbohydratesorhydrates
of carbon due to the chemical empirical formula
[Cm(H2O)n} to proteins and lipids [1–3]. Glycosylation
has many functions in a cell: it allows correct folding
of proteins (some proteins do not fold correctly unless
they are glycosylated ﬁrst), confers stability (some
unglycosylated proteins are more rapidly degraded),
allows cell–cell adhesion (e.g. surface glycoproteins
are directly involved in the biological functions of
lymphocytes), and modulates intracellular signalling
pathways (glycosylation of proteins may enhance or
inhibit enzymes’ activities) [1–3].
There are many types of glycosylation: (i) phospho-
linked, where the sugar is attached via the phosphate of
a phospho-serine; (ii) C-linked, where the carbohydrate
is added to a carbon on a tryptophan side chain; and (iii)
the formation of a GPI (glycosylphosphatidylinositol)
anchor (glypiation), where the sugar is linked to
phosphoethanolamine, which in turn is attached to the
terminal carboxy group of the protein. Furthermore,
two other general classes of protein-bound glycans are
represented by N- and O-linked glycans. In N-linked
glycosylation, the carbohydrate is attached to a nitrogen
of asparagine or arginine side chains. The modiﬁcation
of N-linked glycans within the Golgi does not follow
a linear pathway. As a result, ﬁve different N-glycan
linkages have been reported, of which GlcNAc (N-
acetylglucosamine)toasparagine(GlcNAcβ1-Asn)isthe
most common [1,3]. Although there have been several
published reports of nucleocytoplasmic or cytoplasmic
N-glycans, there exists no deﬁnitive structural evidence
that N-glycans actually occur on cytoplasmic or nuclear
proteins nor on the cytoplasmic portions of membrane
proteins [1]. In O-linked glycosylation, the carbohydrate
is attached to the hydroxyl oxygen of serine, threonine,
tyrosine,hydroxylysineorhydroxyprolinesidechainsof
nuclear and cytoplasmic proteins [1–3].
WHAT IS O-GlcNAcYLATION?
Cellular glycoproteins were initially thought to be
targeted, after their synthesis, only to luminal or
extracellular compartments. However, in 1984, Torres
and Hart [4], who were interested in characterizing
the role of cell-surface saccharides in the development
and functions of lymphocytes, described a novel
carbohydrate (GlcNAc)-peptide linkage, which was
present on proteins localized in the cytosol and
the cyto- and nucleo-plasmic faces of membranous
organelles. In 1989, Kelly and Hart [5] described
that Drosophila polytene chromosomes (i.e. polytene
chromosome spreads prepared from the salivary glands
of third instar stage D. melanogaster larvae) contained a
surprisingly large amount of terminal GlcNAc residues
alongtheirlengths.Nearlyallofthechromatin-associated
GlcNAc moieties existed as single monosaccharide
residues attached to proteins by an O-linkage [O-
GlcNAc (O-linked GlcNAc)] [5]. In addition, in the
late 1980s, the glycosyltransferase responsible for the
addition of GlcNAc to proteins was found to be
orientated with its active site in the cytoplasm, and
the ﬁrst proteins modiﬁed with O-GlcNAc were
described [6].
Theseinitialobservations,whichindicatedafunctional
orbiologicalsigniﬁcancefortheO-linkageofGlcNActo
proteins,ledtothetermO-GlcNAcylation.Accordingly,
O-GlcNAcylation is currently deﬁned as an unusual
form of protein glycosylation, where a single-sugar
(O-GlcNAc) is added (β-attachment) to the hydroxy
moiety of serine and threonine residues of nuclear and
cytoplasmic proteins.
It is unusual in that it is found in nuclear and
cytoplasmic proteins, representing the ﬁrst reported
example of glycosylated proteins found outside of
the secretory channels. Unlike other peptide-linked
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Table 1 Examples of PTMs of proteins
Modiﬁcation Description Donor Target Reference(s)
Acetylation (an example of
acylation)
Introduction of an acetyl group (-COCH3)
(the acyl derivative of acetic acid)
catalysed by acetyltransferases
Acetyl-CoA α-Amino group at the N-terminus
(N-terminal acetylation) or ε-amino
group on the side chain of lysine
residues
[106,107]
Methylation (an example
of alkylation)
Addition of an alkyl group (methyl,
–C H 3) catalysed by
methyltransferases
S-Adenosylmethionine (SAM) Nitrogen and oxygen molecules (lysine
residues, guanidino moiety of
arginine, R-group amides or R-group
carboxylates of glutamate and
aspartate)
[108]
Phosphorylation Addition of a phosphate group (PO4
3−)
by a kinase
ATP Serine, threonine and tyrosine (O-linked),
or histidine (N-linked)
[109]
Nitration Addition of a nitro triatomic group
(-NO2)
NO Tyrosine or cysteine residues to form
nitrotyrosine
[110,111]
Nitrosylation or
nitrosation∗
Addition of an equivalent NO to a thiol,
metal, amine or hydroxy aromatic
group
NO diatomic group or nitrosyl
group
Thiol, metal, amine or hydroxy aromatic
group
S-Nitrosation or
S-nitrosylation†
Incorporation of the NO moiety into a
sulfur atom to form an S-NO bond.
NO Cysteine residue
Sulfation Addition of a sulphate (SO4
2−) catalysed
by tyrosylprotein sulfotransferase
(TPST) in the Golgi apparatus
PAPS (3 -phosphoadenosyl-5 -
phosphosulfate)=
2ATP+SO4
−2
Tyrosine residues [112]
Prenylation (or
isoprenylation)
Addition of an isoprenoid group [e.g.
farnesol (farnesylation) or
geranylgeraniol (geranylgeranylation)]
Isoprenoid compounds (15 carbon
farnesyl groups and 20
carbon geranylgeranyl groups)
Cysteine residues at the C-terminus of
proteins
[113]
S-Sulfhydration Addition of hydrogen sulﬁde (H2S) Cysteine residue [114,115]
S-Glutathionylation Reversible formation of protein mixed
disulﬁdes (protein-SSG) with
glutathione (GSH)
Glutathione (GSH) Cysteine residue [116]
Glycosylation‡ Addition of saccharides or a glycosyl
group by glycosyltransferases
Nucleotide sugar Nitrogen of asparagine or arginine
side-chains (N-linked glycans); hydroxy
oxygen of serine, threonine, tyrosine,
hydroxylysine or hydroxyproline side-
chains (O-linked glycans); oxygens on
lipids such as ceramide
[1–3]
∗The terms nitrosation and nitrosylation are distinguished by the addition of the NO diatomic group and nitrosyl group NO respectively. However, in NO species, both groups are the
same and inclusion of the ‘-yl-’ in terms describing the PTM is widespread.
†To trigger S-nitrosylation, NO is converted into dinitrogen trioxide (N2O3) with an electron acceptor such as oxygen, followed by partial dissociation into [+ON–NO2−]. As this
reaction occurs, the nitrosonium (NO+) moiety can interact with the nucleophile sulfur atom to form S-nitrosothiol (SNO) to the protein’s thiol group.
‡The term glycation is used for the chemical or non-enzymatic linkage of a sugar molecule, such as fructose or glucose, to proteins or lipids. Glucose, for example, can slowly
condense non-enzymatically with protein amino groups forming, initially, a Schiff base that may rearrange to form the Amadori product. The Amadori product subsequently degrades into
α-oxoaldehyde compounds such as 1- and 3-deoxyglucosones, which can react with proteins to form cross-links, as well as chromo/ﬂuorophoric adducts called Maillard products (or AGEs).
monosaccharides, the β-linked GlcNAc-Ser/Thr does
not become further replaced by other sugars, remaining
a single monosaccharide modiﬁcation of the protein
to which it is attached. O-GlcNAcylation is widely
dispersed among eukaryotes, from protozoa to higher
mammals. The amino acid consensus sequence or
glycosylation motifs for the formation of O-GlcNAc
bonds have not yet been found. However, information
relating to the polypeptide domains that favour
O-GlcNAc attachment has been obtained and seems to
involve PEST [proline (P), glutamic acid (E), serine (S),
and threonine (T)] sequences [7].
In the present review, we will brieﬂy comment on
general aspects of O-GlcNAcylation and provide an
overview of what has been reported for this PTM
in the cardiovascular system. We will then speciﬁcally
address whether signalling molecules involved in
phosphorylation and redox signalling can be modiﬁed by
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O-GlcNAc and will discuss the physiological/
pathological implications this may have.
A BRIEF OVERVIEW OF O-GlcNAcYLATION
Results from proteomic studies have suggested that more
than 1500 proteins in the cell are modiﬁed by O-GlcNAc
[8–11]. These proteins belong to almost every functional
class of proteins, including transcription or translation
factors, cytoskeletal proteins, nuclear pore proteins,
RNA polymerase II, tumour suppressors, hormone
receptors, phosphatases and kinases [8–11]. A database
of O-GlcNAcylated proteins and sites, dbOGAP, was
recently created and is based primarily on literature
published since O-GlcNAcylation was ﬁrst described in
1984.Thedatabasecurrentlycontains∼800proteinswith
experimental O-GlcNAcylation information. The O-
GlcNAcylatedproteinsareprimarilynucleocytoplasmic,
and include membrane- and non-membrane bounded
organelle-associatedproteins[12].AnO-GlcNAcylation
site prediction system (O-GlcNAcScan) based on nearly
400 O-GlcNAcylation sites was also developed [13].
Both the database and the prediction system are
publicly available at http://cbsb.lombardi.georgetown.
edu/OGAP.html and http://cbsb.lombardi.georgetown.
edu/ﬁledown.php respectively [12,13].
The attachment of the single-sugar β-N-
acetylglucosamine via an O-linkage to serine/threonine
residues is controlled by two highly conserved enzymes
OGT [O-GlcNAc transferase or UDP-NAc transferase
(uridine diphospho-N-acetylglucosamine:polypeptide
β-N-acetylglucosaminyl transferase] and OGA (β-N-
acetylglucosaminidaseorO-GlcNAcase).WhereasOGT
catalyses the addition of O-GlcNAc to the hydroxy
group of serine and threonine residues of a target
protein using UDP-GlcNAc as the obligatory substrate,
OGA catalyses the hydrolytic cleavage of O-GlcNAc
from post-translationally-modiﬁed proteins [14–16]
(Figure 1).
A single OGT gene is located on the X chromosome
in humans and mice [17]. In some tissues, such as skeletal
muscle, kidney and liver, three distinct isoforms of OGT
havebeenidentiﬁed,includingtwo110 kDasubunitsand
one 78 kDa subunit, which can assemble into multimers,
and smaller mitochondrial isoforms [18]. Each variant
contains a C-terminal catalytic domain, but differs in
the number of TPRs (tetratricopeptide repeats) within
its N-terminal domain. The TPRs serve as protein–
protein interaction modules that appear to target OGT
to accessory proteins and potential substrates, such as
the related OIP106 (OGT-interacting protein 106) and
PP1(proteinphosphatase1)[19].Phylogeneticanalysisof
eukaryotic OGTs indicates that plants have two distinct
OGTs,SEC(secretagent)-andSPY(spindly)-like,which
originated in prokaryotes and are involved in diverse
Figure 1 The HBP
After entering the cell via a glucose transporter and being converted into
glucose 6-phosphate (glucose-6P) by a hexokinase and into fructose 6-phosphate
(fructose-6P), glucose can either be used in the glycolytic pathway or the HBP. The
HBP uses fructose 6-phosphate to form glucosamine 6-phosphate (glucosamine-6P),
with glutamine serving as the donor of the amino group. The reaction is catalysed
by the rate-limiting enzyme GFAT. Glucosamine 6-phosphate is rapidly acetylated
through the action of acetyl-CoA:D-glucosamine-6-phosphate N-acetyltransferase
(GAT) and isomerized to N-acetylglucosamine-1-phosphate (GlcNAc-1-P) and
activated, via the action of UDP-GlcNAc pyrophosphorylase (AGX), to UDP-GlcNAc
that serves as the donor of O-GlcNAc for OGT activity. Glucosamine can also
enter the cell through the glucose transporter and is rapidly phosphorylated by
hexokinase yielding glucosamine 6-phosphate, thereby bypassing the rate-limiting
ﬁrst step of the HBP. S, serine; T, threonine;
plant processes, including responses to hormones and
environmental signals, circadian rhythms, development,
intercellular transport and virus infection [20].
The donor substrate for OGT activity UDP-
GlcNAc is a terminal product of the HBP (hexosamine
biosynthesis pathway) (Figure 1). Flux through the HBP
and UDP-GlcNAc levels change rapidly in response to
many different nutrients, such as glucose, fatty acids and
aminoacids[21],alteringtheextentofO-GlcNAcylation
of many proteins. Non-esteriﬁed ‘free’ fatty acids can
increase HBP ﬂux by inhibiting glycolysis, resulting
in elevated fructose 6-phosphate levels. Acetyl-CoA,
produced by fatty acid metabolism, serves as the donor
for the acetylation of glucosamine in the formation of
UDP-GlcNAc [21,22]. Exogenously, small amounts of
glucosamine can dramatically increase UDP-GlcNAc
pools in cells [23].
Since OGT activity is exquisitely sensitive to UDP-
GlcNAc concentrations (Figure 1), O-GlcNAcylation
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Figure 2 Interplay between O-GlcNAcylation and phosphorylation of proteins
Both phosphorylation and O-GlcNAcylation occur on serine/threonine (Ser/Thr) residues of proteins. In speciﬁc proteins, there is a competitive relationship between
O-GlcNAc and O-phosphate for the same serine/threonine residues, although there can be adjacent or multiple occupancy for phosphorylation and O-GlcNAcylation
on the same protein. The interplay between phosphorylation and O-GlcNAcylation creates molecular diversity by altering speciﬁc protein sites that regulate protein
functions and signalling events. Tyr, tyrosine.
may act as a sensor for the general metabolic state
of the cell. Consistent with this idea, O-GlcNAc has
been intricately linked to cell survival induced by
many forms of cell stress [24–26]. Interestingly, glucose
deprivation also increases protein O-GlcNAcylation in
some cancer cells [27–29]. The mechanisms of this
paradoxical phenomenon seem to involve increased
OGT expression and p38 MAPK (mitogen-activated
protein kinase)-dependent OGT activity and decreased
O-GlcNAc modiﬁcation of OGT, as well as reduced
O-GlcNAcase activity and decreased hexosamine ﬂux-
induced up-regulation of ncOGT (nucleocytoplasmic
OGT) [27–29]. However, a recent study has shown that
increased glycosylation induced by glucose deprivation
is actually modiﬁcation by N-GlcNAc2, and suggests
that repression of mature N-linked glycoproteins due
to increased levels of N-GlcNAc2-modiﬁed proteins
represents a newly recognized pathway for effective use
of sugar under stress and deprivation conditions [30].
O-GlcNAcase or OGA appears to use substrate
catalysis involving the 2-acetamido group and contains
an N-terminal glycosidase domain and a putative
C-terminal histone acetyltransferase domain [31]. Two
distinctisoformsofOGAhavebeendescribed,a130 kDa
and a 75 kDa variant, which differ in their C-terminus.
Whereas the 130 kDa or ‘long OGA’ contains a distinct
N-terminal glycosidase domain and the C-terminal
histone acetyltransferase domain, the 75 kDa or ‘short
OGA’ lacks the C-terminal domain. One important
functional aspect in the existence of these two splices
is their differential sensitivity to previously described
potent OGA inhibitors. For example, the short OGA
exhibits comparative resistance to PUGNAc [O-(2-
acetamido-2-deoxy-D-glucopyranosylidene)amino-N-
phenylcarbamate] and NAG-thiazoline [1,2-dideoxy-2´ -
methyl-a-d-glucopyranoso-[2,1-d]- 2 -thiazoline], but
is very sensitive to α-GlcNAc thiolsulfonate [11,15,31].
Inhibition of OGT and OGA represents an area of great
interest in O-GlcNAcylation research, which is evident
from the increasing number of studies addressing the
molecular mechanisms of the enzymes for the addition
and removal of O-GlcNAc [32–35].
O-GlcNAcYLATION AND PROTEIN
PHOSPHORYLATION
The dynamic addition of O-GlcNAc to proteins has
been implicated in modulating protein behaviour via one
potential mechanism that includes a complex interplay
between O-GlcNAcylation and phosphorylation. Many
phosphorylation sites are also known glycosylation sites,
and this reciprocal occupancy may produce different
activities or alter stability in the target protein [36,37]
(Figure 2). The competition between O-GlcNAcylation
and phosphorylation for the same or neighbouring
residues has been termed the ‘Yin–Yang’ hypothesis and
h a sb e e nr e p o r t e di nav a r i e t yo fp r o t e i n s[ 3 8 ] .
The interplay between these two PTMs is not always
reciprocal, since some proteins can be concomitantly
phosphorylated and O-GlcNAcylated, and the adjacent
phosphorylation or O-GlcNAcylation can regulate the
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addition of either moiety. The cross-talk between O-
GlcNAcylation and phosphorylation also exists among
distantly located sites and they inﬂuence each other
by regulating the activities or localization of other
cycling enzymes. For example, OGT is directly activated
by tyrosine phosphorylation and is itself O-GlcNAc-
modiﬁed [38]. OGT also forms a stable and active
complex with PP1β and PP1γ in rat brain [19]. The
association between OGT and PP1 is particularly
intriguing, as it may provide a direct mechanism to
couple O-GlcNAc to the dephosphorylation of speciﬁc
substrates.
A recent report has shown that rat brain assembly
protein AP180, which is involved in the assembly of
clathrin-coated vesicles in synaptic vesicle endocytosis,
contains an O-GlcNAc-P (phosphorylated O-GlcNAc)
within a highly conserved sequence (O-GlcNAc or O-
GlcNAc-P, but not phosphorylation alone, was found
at Thr310) [39]. O-GlcNAcylation was thought to be a
terminal modiﬁcation, i.e. the O-GlcNAc was not found
to be additionally modiﬁed. The existence of protein
glycosyl phosphorylation (O-GlcNAc-P) adds further
complexity to the phosphorylation–O-GlcNAcylation
interplay.
Lastly, the interplay between O-GlcNAc modiﬁc-
ation and phosphorylation may not be limited to
serine/threonine phosphorylation, but may also include
tyrosine phosphorylation. On the basis of the higher
prevalence of tyrosine phosphorylation among O-
GlcNAc-modiﬁed proteins (∼68% compared with 2%
in non-O-GlcNAc-modiﬁed proteins), Mishra et al. [40]
suggested that tyrosine phosphorylation plays a role
in the interplay between O-GlcNAc modiﬁcation and
serine/threonine phosphorylation in proteins.
This clearly shows that the interplay between O-
GlcNAcylation and phosphorylation is both complex
and very extensive. As with any PTM, mapping the
attachment sites is a prerequisite toward understanding
the biological functions of O-GlcNAcylation [41,42].
The development of chemical tools coupled to mass
spectrometry has greatly facilitated the localization of
O-GlcNAc to short peptide sequences within proteins,
and this combination can be used to determine exact
glycosylation sites [42]. Since a direct observation of
the O-GlcNAc moiety by mass spectrometry during
CID (collision-induced dissociation) is difﬁcult, as the
glycosidic linkage is labile and readily cleaved [43],
alternative and newer approaches, such as BEMAD
(β-elimination followed by Michael addition with
dithiothreitol), ETD (electron transfer dissociation)
and ECD (electron capture dissociation), have been
used [8,44–46]. In addition, oxogalactose–biotin tagging
or azidogalactose–biotin tagging have been combined
with BEMAD to identify speciﬁc glycosylation sites
[16,43,47]. Furthermore, several chemical approaches
to monitor changes in O-GlcNAcylation levels in
response to cellular stimuli have been developed lately.
A FRET (ﬂuorescence resonance energy transfer)-based
sensor has been recently developed for the detection
of O-GlcNAc dynamics in living cells [48]. This
approach provides an alternative to examine changes in
the intracellular signalling pathways and the dynamics
of O-GlcNAcylation on speciﬁc protein substrates
and will help to clarify the cross-talk between O-
GlcNAc and other PTMs. For further information
on the complex interplay between O-GlcNAcylation
and phosphorylation, please refer to the following
comprehensive and excellent reviews [17,36,49,50].
O-GlcNAcYLATION AND THE
CARDIOVASCULAR SYSTEM
A series of studies have consistently shown that
activation of the pathways leading to O-GlcNAc
formation improves cardiac cell survival and function
after acute myocardial stress conditions [I/R (ischaemia/
reperfusion) injury and trauma-haemorrhage], whereas
inhibitionofO-GlcNAcformationdecreasesmyocardial
cell survival [14,24,51–53]. This is in agreement with the
suggestion that stress leads to a transient increase in O-
GlcNAc levels that is associated with increased tolerance
to stress [11,25,54]. The mechanisms associated with the
beneﬁcial or protective effects of O-GlcNAc on cardiac
functionwillbediscussedbelowandarealsosummarized
in Figure 3.
On the positive or beneﬁcial effects
of O-GlcNAc
Administration of glucosamine, as well as an OGA
inhibitor(PUGNAc,which increases O-GlcNAclevels),
to a rat model of trauma-haemorrhage increased tissue
levels of O-GlcNAc on proteins, improved cardiac
function, and reduced circulating levels of inﬂammatory
cytokines and activation of NF-κB (nuclear factor
κB) [53]. In primary cultured cardiomyocytes, both
glucosamine and overexpression of OGT attenuated LPS
(lipopolysaccharide)-induced expression of inﬂammat-
ory markers and activation of NF-κB [23], suggesting
that the beneﬁcial actions of O-GlcNAc involve anti-
inﬂammatory effects.
O-GlcNAcylation also confers cytoprotection in
the heart via attenuating the formation of the mPTP
(mitochondrialpermeabilitytransitionpore)andthesub-
sequent loss of mitochondrial membrane potential. O-
GlcNAcylation-induced attenuation of mPTP formation
is associated with decreased Ca2+ overload and ROS
(reactive oxygen species) generation [55,56].
Protective effects of O-GlcNAc have also been
reported in other I/R models. Accordingly, coronary
ligation to induce heart failure in mice increases
cardiac OGT expression and levels of O-GlcNAc
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Figure 3 O-GlcNAc formation in the cardiovascular system produces both protective and harmful effects
The effects of O-GlcNAcylation in the cardiovascular system may depend on whether they are acute or chronic effects on the initial cellular metabolic/energetic/redox
status of the cell and on the speciﬁc proteins that are O-GlcNAc-modiﬁed in each cell type/tissue/organ.
proteins in the surviving remote myocardium. Genetic
deletion of cardiomyocytes OGT reduced cardiac O-
GlcNAcylation of proteins and signiﬁcantly exacerbated
cardiacdysfunction[57].Intraperitonealglucosaminead-
ministrationtoratsthatunderwentmiddlecerebralartery
occlusion reduced infarct volume, motor impairment
and neurological deﬁcits, and suppressed post-ischaemic
microglial activation and LPS-induced up-regulation
of pro-inﬂammatory mediators. The anti-inﬂammatory
effects of glucosamine were mainly attributable to
its ability to inhibit nuclear NF-κB activation [58].
Interestingly, glucosamine prevented LPS-induced p65
O-GlcNAcylation [58], which is somewhat puzzling
since PTM of the NF-κB p65 subunit by O-GlcNAc
(Thr322 and Thr352) has been reported to decrease binding
to IκBα (inhibitory κBα) and increase transcriptional
NF-κB activity [59].
Acute administration of glucosamine or the OGA
inhibitor PUGNAc also inhibited acute inﬂammatory
and neointimal responses in a model of endoluminal
arterial injury. O-GlcNAc-modiﬁed protein levels
decreased markedly in injured arteries, but glucosamine
and PUGNAc prevented the decrease in O-GlcNAc
levels, as well as the expression of pro-inﬂammatory
mediators and neutrophil/monocytes inﬁltration, and
reduced neointima formation in injured arteries,
indicating that O-GlcNAcylation in the vasculature may
have anti-inﬂammatory and vasoprotective effects [60].
Accordingly, in endothelial cells, glucosamine decreased
the expression of inﬂammatory markers and abrogated
the phosphorylation of p38 MAPK and NF-κB [61,62],
but, paradoxically, glucosamine was shown to have pro-
oxidative properties [61].
The reports described above highlight that cardiac
proteinO-GlcNAcylationmayserveasanautoprotective
alarm or stress response. Although O-GlcNAcylation
improves cardiac cell survival during acute stress
(e.g. hypoxia, ischaemia and oxidative stress), limiting
O-GlcNAcylation exacerbates cardiac cell damage
(Figure 3). It should be noted, however, that the acute
anti-inﬂammatory effects of elevated O-GlcNAc in
the heart cannot be generalized to every other cell.
For example, O-GlcNAc is crucial for T- and B-cell
activation. O-GlcNAc modiﬁcation, which increases
shortly after activation of lymphoid cells, seems to be
requiredfornucleartranslocationoftranscriptionfactors.
OGT is also required for the early activation of B-cells
mediated by stimulation of the B-cell receptor. Both
NF-κB and NFAT (nuclear factor of activated T-cells)
are glycosylated with O-GlcNAc after direct binding to
OGT [63,64].
Although acute increases in O-GlcNAc appear to
be protective, O-GlcNAcylation seems to contribute to
cardiac and vascular dysfunction in conditions of chronic
stress, as will be discussed next.
On the negative or harmful effects
of O-GlcNAc
IncreasedglucosemetabolismviatheHBPandassociated
increase in O-GlcNAc levels on proteins have been
shown to contribute to the adverse effects of diabetes
on the heart [65] (Figure 3). In diabetes models,
O-GlcNAcylation leads to impaired cardiomyocyte
hypertrophic and cell signalling pathways [65], and is
associated with defects in cardiomyocyte mechanical
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function(impairedrelaxation)[66].NegativeeffectsofO-
GlcNAcylationhavealsobeenreportedinthevasculature
[67–69].
In the vascular system, OGA has been shown to
be expressed in both endothelial cells and smooth
muscle cells of rat aortas [70]. OGT and GFAT
(glutamine:fructose-6-phosphate amidotransferase) have
also been identiﬁed in vascular cells and changes in the
vascular expression of these enzymes have been reported
in hyperglycaemic/diabetic, aging and hypertensive con-
ditions [69–71]. Subsequent studies have demonstrated
that diabetes, hyperglycaemia and arterial hypertension
result in lower endothelial eNOS (endothelial NO
synthase) protein activation, but increased O-GlcNAc
modiﬁcation (and possibly inactivation) of eNOS
[67–69].
Our group has shown that increased levels of
O-GlcNAcylation augments vascular responses to
contractile stimuli [72] and that O-GlcNAc-modiﬁed
proteins are increased in the vasculature of DOCA
(deoxycorticosterone acetate) salt hypertensive rats [69].
In addition, ET-1 (endothelin-1), which plays a major
role in vascular dysfunction associated with salt-
sensitive forms of hypertension, directly activates O-
GlcNAcylation of vascular proteins and this PTM
mediates important vascular effects of the peptide
[73,74]. O-GlcNAcylation seems to contribute to the
vascular effects of ET-1 via activation of the RhoA/Rho-
kinase pathway. Of importance, augmented contractile
responses induced by increased O-GlcNAc levels in
response to PUGNAc (an OGA inhibitor) are abolished
by Rho-kinase inhibition (Y-27632) [15,74]. Glucosa-
mine, which induces O-GlcNAcylation of proteins,
also increases vessel contraction via augmentation
of RhoA activity [75]. These studies indicate that
O-GlcNAcylation negatively interferes with vascular
function, mainly vascular reactivity, and that O-GlcNAc
may play a direct role in mediating vascular dysfunction
associated with arterial hypertension and diabetes.
Some confusion/surprise may arise when one initially
looks at the O-GlcNAcylation literature on the
cardiovascular system. It seems that O-GlcNAc is
protective in the heart and harmful in the vasculature.
However, there are many avenues that need to be
considered before one can classify O-GlcNAcylation as
‘good/protective’or‘bad/harmful’.First,acutecompared
with chronic effects of O-GlcNAcylation must be
considered (Figure 3). It is possible that acute increases
in cardiovascular O-GlcNAc-modiﬁed proteins may
counteract stressor stimuli and have protective actions,
whereas chronic cardiovascular O-GlcNAcylation may
contribute to further cardiac/vascular dysfunction via
modulation of other signalling pathways. Secondly, the
initial cellular conditions when components of the O-
GlcNAc system are manipulated (OGA/OGT/GFAT
overexpression, deletion and pharmacological inhibition
etc). Removing or adding O-GlcNAc to cells may
produce opposite/differential effects depending on
the initial metabolic/energetic/redox status of the
cell. Thirdly, manipulations that globally increase O-
GlcNAcylation may (and will) produce differential
effectsbasedonthespeciﬁcproteinsthatareO-GlcNAc-
modiﬁed in each cell type/tissue/organ.
It should be noted that it is not only in the
cardiovascular system that, O-GlcNAcylation has been
shown to have ‘double dagger, Yin–Yang, paradoxical,
friend–foe or positive–negative’ actions. Quoting Marsh
and Chatham [76]: “Our knowledge of the role(s) of
O-GlcNAc on the regulation of the cardiovascular
system is in its infancy”. Consequently, much needs
to be done/answered before we have a clear picture of
the ‘cardiovascular O-GlcNAcylation world’. Therefore
futureinvestigationsarenecessaryinordertocharacterize
the cardiovascular effects of O-GlcNAcylation and
speciﬁc cardiac and vascular O-GlcNAcylated proteins
(and to identify speciﬁc modiﬁcation sites on these
proteins), as well as to identify the mechanisms that
regulate OGT and OGA activity in cardiac and vascular
cells.
ROS AND O-GlcNAcYLATION
In this section, we will address whether signalling
molecules involved in redox signalling can be modiﬁed
byO-GlcNAcandthepossibleimplicationstheinterplay
between O-GlcNAcylation and ROS generation may
have. As will become apparent, experimental evidence
indicatesthattheinteractionsbetweenO-GlcNAcylation
and oxidation of proteins are important not only for cell
regulation in physiological conditions, but also under
pathological states where the interplay may become
dysfunctional and thereby exacerbate cellular injury.
Increased levels of ROS, deﬁned as a disruption of
redox signalling and termed oxidative stress, has been
consistently reported in various chronic diseases and
conditions, including those where O-GlcNAcylation
has been implicated as a mechanistic contributor for
the associated organ injury/protection (diabetes, arterial
hypertension, Alzheimer’s disease, aging and ischaemia)
[77–80].
ROS participate in many intracellular signalling
pathways leading to changes in gene transcription and
protein synthesis, and consequently in cell function.
In the cardiovascular system, ROS are produced in all
cell types, including cardiac myocytes, endothelial cells,
smooth muscle cells and cells in the adventitia, and are
tightly regulated by antioxidants, including SOD (su-
peroxide dismutase), catalase, thioredoxin, glutathione,
vitamins and other small molecules [81,82]. However,
under pathological conditions, ROS production is
increased, leading to endothelial dysfunction, increased
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Figure 4 Interplay between ROS, phosphorylation and O-GlcNAcylation
Evidence indicates that ROS stimulates not only phosphorylation, but also O-GlcNAcylation of proteins. On the other hand, augmented O-GlcNAc induces ROS production
and/or up-regulation of stress-related proteins. Increased production of ROS has been consistently reported in various chronic diseases and conditions, including those
where O-GlcNAcylation has been implicated as a mechanistic contributor or protective agent. The O-GlcNAc symbol indicates proteins that have already been identiﬁed
as O-GlcNAcylated, according to the dbOGAP. Numbers in parenthesis indicate the dbOGAP ID. Catalase (OG00108–OG00119); glutathione transferase (OG00341,
OG00342, OG01049, OG01062 and OG003437); SOD (OG00848 and OG01057); thioredoxin (OG01067, OG010679, OG00648 and OG006487); NO synthase (OG00587,
OG005878, OG00589, OG00590, OG005891 and OG005892); NADH dehydrogenase [ubiquinone] 1α subcomplex subunit 9 (OG00557–OG00561). FAK, focal adhesion
protein.
contractility, VSMC growth, monocyte migration, lipid
peroxidation, inﬂammation and other processes con-
tributing to cardiovascular damage [77,81,82]. Although
oxidative stress may not be the sole aetiology for these
dysfunctional events, it ampliﬁes vascular damage in the
presence of other vasoactive factors [77,83].
Physiological or chemical stress normally induces
signal transduction events that involve the activation
and/or production of molecules and proteins that
diminish the effects of the deleterious signalling [51].
Protein phosphorylation is typically the mechanism
associated with these signal transduction pathways.
However, in addition to modulating the activity of
speciﬁc protein kinases and phosphatases [84–88],
ROS also stimulate the HBP and, consequently, O-
GlcNAcylation [89]. For instance, increased production
of ROS by the mitochondria induces both changes
in phosphorylation and O-GlcNAcylation of many
proteins, including mitochondrial proteins, which would
increase tolerance of mitochondria to stress [14,52].
The interplay between O-GlcNAc regulation of ROS
will be discussed, i.e. ROS leading to activation of
the HBP and activation of the HBP inducing ROS
generation or oxidative stress (Figure 4). Most of the
examples of the HBP inducing oxidative stress are
associated with hyperglycaemia. This is consistent with
the idea that increased ROS production activates the
ﬁve major pathways involved in the pathogenesis of
hyperglycaemic/diabetic complications: polyol pathway
ﬂux, increased formation of AGEs (advanced glycation
end products), increased expression of RAGE (receptor
for AGEs) and its activating ligands, activation of PKC
(protein kinase C) isoforms and overactivity of the HBP
(or augmented O-GlcNAcylation) [80].
ExperimentalevidenceofROSleadingtotheactivation
of the HBP pathway will be described below. Ngoh
et al. [90] have shown that pharmacological induction
of endoplasmic reticulum stress in neonatal rat cardiac
myocytes augmented O-GlcNAc signalling. In addition,
Jones et al. [52] have shown that, when cardiac
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myocytes were submitted to different durations of H2O2
incubation, O-GlcNAc levels were increased early and
gradually decreased after 45 min. Furthermore, oxidative
stress associated with hyperglycaemia not only increases
HBP ﬂux, but also ampliﬁes inﬂammation and impairs
endothelial function [91]. Of interest, azaserine, a GFAT
inhibitor, not only inhibits the HBP pathway, but it is
also a strong antioxidant, and prevents inﬂammation and
the impairment of endothelium-dependent relaxations
associated with hyperglycaemia [91].
O-GlcNAc depletion in mesangial cells [by shRNA
(short hairpin RNA) directed against OGT] prevented
high-glucose-induced ROS formation. OGT shRNA
alsodecreasedhigh-glucose-stimulatedp38MAPK,JNK
(c-Jun N-terminal kinase) and ASK1 (apoptosis signal-
regulating kinase 1) activation, indicating that renal O-
GlcNAcylation is coupled to pro-ﬁbrotic p38 MAPK
signalling by high glucose, possibly as a consequence
of increased ROS [92]. The authors speculated that O-
GlcNAc increases the phosphorylation of the NADPH
oxidase subunit p47phox, through p38 MAPK activation,
and up-regulates the expression of the NADPH oxidase
subunit Nox4 [92]. Reinforcing this view, a p38 MAPK
inhibitor, SB203580, has been shown to block high-
glucose-induced increases in ROS in mesangial cells [93].
ROS-induced O-GlcNAcylation has also been
reported in cultured 3T3-L1 adipocytes. In these
cells, urea induces ROS production, which increases
modiﬁcation of insulin signalling molecules by O-
GlcNAc and reduces insulin-stimulated IRS (insulin
receptor substrate), Akt phosphorylation and glucose
transport. Similarly, uraemic mice have increased
ROS production, modiﬁcation of insulin signalling
molecules by O-GlcNAc and become insulin-resistant
and glucose-intolerant. Treatment with the SOD/catalase
mimetic {MnTBAP [Mn(III) tetrakis (4-benzoic acid)
porphyrin]} normalizes O-GlcNAc modiﬁcation of
insulin signalling molecules in visceral fat and corrects
systemic insulin resistance and glucose intolerance [94].
In the opposite direction, activation of the HBP has
been shown to induce ROS generation and oxidative
stress. Accordingly, Singh et al. [95] have demonstrated
that both high glucose and glucosamine induce mesangial
cell ROS generation, cell-cycle arrest and apoptosis, and
some of these effects are mediated by its metabolism via
the HBP. In addition, in a microarray study using mouse
oligochip arrays, glucosamine mimicked several gene
expression patterns of high glucose and induced genes
involved in oxidative stress, including the thioredoxin-
interacting protein, an inhibitor of thioredoxin and
antioxidative stress mechanisms. Glucosamine also
down-regulated the expression of oxidative stress
resistance genes, suggesting a possible mechanism for
high glucose and glucosamine-induced oxidative stress in
renal mesangial cells [96]. Furthermore, hyperglycaemia
induces activation of GPX1 (glutathione peroxidase 1),
an antioxidant enzyme essential for cell survival during
oxidative stress. Activation of GPX1 is mediated by O-
GlcNAcylation of this enzyme [97].
The regulation of FoxO1 (forkhead box O1) by
O-GlcNAc is another example of the interlacing of
O-GlcNAc modiﬁcation with ROS. The transcription
factor FoxO1 [FKHR (forkhead in rhabdosarcoma)],
which regulates apoptosis, cell cycle, metabolism and
oxidative stress, has recently been shown to be O-
GlcNAcylated [14,98]. O-GlcNAc modiﬁcation of
FoxO1 leads to its activation [99], which in turn induces
the transcription of oxidative stress response enzymes,
such as catalase and Mn-SOD (manganese SOD).
Furthermore, hyperglycaemia-induced increases in HBP
ﬂux and the subsequent increases in O-GlcNAcylation
of the transcription factor Sp1 (speciﬁcity protein
1) in cultured endothelial cells have been linked
to augmented mitochondrial superoxide production
[100].
A recent report has shown that AGEs/RAGE
activation increases I/R-induced endothelial injury by
increasing oxidative/nitrative injury and subsequent
nitrative inactivation of thioredoxin [101]. Interestingly,
AGEs, or more speciﬁcally, the AGE carbon precursor
methylglyoxal, have been shown to increase ROS
formation, apoptosis, MAPK activation and nuclear O-
GlcNAcylation in fetal human cardiac myocytes [102].
Other players may contribute to the link between
O-GlcNAc modiﬁcation and oxidative stress. A
strong candidate is ET-1, which has been shown to
induce oxidative stress [103,104] and to increase O-
GlcNAcylation levels [73,74]. As discussed above, ET-
1 augments vascular O-GlcNAcylation and this PTM
contributes to the vascular changes produced by the
peptide [15,73]. In addition, Callera et al. [103] have
shown that ET-1 mediates oxidative stress in DOCA-
salt hypertension. Interestingly, O-GlcNAc levels are
increased in aortas from DOCA-salt hypertensive rats
and treatment of these rats with an ETA receptor
antagonist prevented augmented O-GlcNAc levels [73],
aswellasdecreasingvascularsuperoxidegeneration[105].
Whether ET-1-induced ROS generation contributes to
the activation of the O-GlcNAc pathway or ET-1-
induced O-GlcNAcylation leads to oxidative stress has
not yet been investigated.
It is clear that there is a critical interplay between
O-GlcNAcylation and ROS generation (and vice versa)
in the cardiovascular system, and that this interplay is
important not only for cell regulation in physiological
conditions, but also under pathological states where
ROS and O-GlcNAc may become dysfunctional and
thereby exacerbate cellular injury. Figure 4 illustrates
the interactions between ROS and O-GlcNAcylation,
and also depicts pro-oxidative and antioxidant proteins
that are regulated by O-GlcNAcylation (proteins that
are either directly O-GlcNAcylated or whose
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expression/activity is altered by changes in O-GlcNAc
levels).
CONCLUSIONS
Our understanding of the O-GlcNAcylation process
(enzymatic regulation, cellular targets and sites for O-
GlcNAc addition, and modulation by other pathways),
aswellasofitsfunctionalimportanceanditscontribution
to (dys)regulation of the cardiovascular system under
different circumstances (e.g. diabetes, ischaemia, trauma-
haemorrhage, aging, arterial hypertension and the
metabolic syndrome), is rapidly increasing.
It is also evident that the direct interactions between
O-GlcNAcylation and phosphorylation and the fact that
both PTMs can interfere with redox signalling (and
vice versa) adds great complexity to our knowledge
of the role(s) of O-GlcNAc on the regulation of the
cardiovascular system.
Thus future investigations into protein O-
GlcNAcylation and cardiovascular signalling
should focus on the characterization of speciﬁc O-
GlcNAcylated proteins, including the identiﬁcation of
the O-GlcNAc-modiﬁed sites. Studies addressing and
identifying the factors involved in regulating OGT
and OGA activity, such as redox signalling mole-
cules and enzymes, are also needed. This will provide
a greater understanding as to how O-GlcNAc exerts
both positive and negative effects in the cardiovascular
system and potentially provides an avenue for targeted
interventions and therapies.
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